US · Healthcare · Biotechnology
EPS came in at -0.03 against a street estimate of -0.01 — a miss of 200.0%.
Analysts rate Phathom Pharmaceuticals Inc a strong buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $19.64.
CONFIDENT Phathom delivered strong Q3 growth, a second consecutive quarter of positive operating profit and cash generation, while reiterating 2026 guidance and advancing access initiatives. Q3 FY26 Management said commercial coverage exceeds 80% of lives and BlinkRx produces higher prior-authorization and fill rates; the $0 co-pay program excludes Massachusetts. Analysts focused on access execution, BlinkRx adoption, potential PCAB competition, margins, guidance and pipeline milestones. Management emphasized office-level education, stable payer coverage, limited one-time margin pressure and continued clinical progress. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 15.41% |
| Medicxi Ventures Management (Jersey) Ltd | 9.23% |
| BlackRock Inc | 5.59% |
| Amvescap Plc. | 4.98% |
| The Carlyle Group Inc | 4.32% |
| Millennium Management LLC | 4.17% |
| Vanguard Capital Management, LLC | 3.28% |
| GW&K Investment Management, LLC | 2.68% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PHATHOM PHARMACEUTICALS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Product Revenue (6 months ended June 30, 2026): $132.6 million vs. $68.0 m | 2026-07-30 |
| Results announced · Q3 2026 PHATHOM PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net revenues: $74.3 million, up 88% vs Q2 2025 ($39.5 million) | 2026-07-30 |
| Company announcement · Q2 2026 PHATHOM PHARMACEUTICALS, INC. — 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company completed enrollment in Phase 2 pHalcon-EoE-201 clinical trial o | 2026-06-23 |
| Shareholder vote results · Q2 2026 PHATHOM PHARMACEUTICALS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • Total votes cast across proposals: approximately 6 | 2026-05-21 |
| Quarterly report · Q1 2026 PHATHOM PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product revenue (Q1 2026): $58.3 million vs. $28.5 million (Q1 2025) — 104% | 2026-04-30 |
| Results announced · Q2 2026 PHATHOM PHARMACEUTICALS Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Q1 2026 net revenues: $58.3 million (104% increase year-over-year from $28.5 mi | 2026-04-30 |
| Proxy statement · Q2 2026 PHATHOM PHARMACEUTICALS, INC. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class I directors for three-year t | 2026-04-07 |
| Annual report FY2025 PHATHOM PHARMACEUTICALS, INC. – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Stock Exchange & Share Data: Common st | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Phathom Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.